Table 9 Animal Studies of VAE Compounds in Breast or Gynaecological Cancer (transplanted human or murine tumours)

Human breast tumour

Breast

Mice

rML 0,3 ng/kg – 3 μg/kg, ip, qd * 5 * 2–4 w

No effect

[129]

Murine breast tumour in mice

C3L5, adenocarcinoma; sc

Mice (C3H7HeJ)

ML I, 1 ng/kg, sc, q3d, day 7–19

160

27.6 lung-metastases

[130]

IL-2, twice 6 × 104 IU/mouse, ip q8h 2 * qd * 5

43

2.3 lung-metastases

Combination of ML 1 & IL-2

37

2.3 lung-metastases

Control

7.5 lung-metastases

ECa, ip

Mice (ICR)

ML I, 80 ng, ip, day 1

70% died after 50 days

[131]

A-chain of ML I, 100 μg, ip, day 1

80% died after 57 days

B-chain of ML I, 10 μg, ip, day 1

80% died after 58 days

Control

100% died after 20 days

ECa, sc

Mice (BALB/c)

VAE 5 kDa peptides, 2 μg, it, day 7

Severe necrosis, infiltration of lymphocytes and macrophages

[122]

ECa, ip

Mice (CD-1)

Vester' Proteins, ip, 0.1 or 1 or 10 μ/kg, qd * 10

ILS: 0, 33, and -33%I

[132]

ECa

Mice

Polysaccharide („Viscumsäure“), ip, qd * 6

Slight effect

[133]

Adenocarcinoma EO 771

Mice

Polysaccharide („Viscumsäure“), ip, qd * 6

Moderate effect

[133]

Murine breast tumour in rats

Walker Carcinosarcoma

Rats

Polysaccharide („Viscumsäure“), ip, qd * 6

Moderate effect

[133]

Other gynaecological tumour

Ovary, SoTü 3, ip

Mice (SCID)

rML 30 ng/kg, ip, qd * 5 * 12

35% mice alive at day 84

40% tumour-free mice at day 84

[134]

rML 150 ng/kg, ip, qd * 5 * 12

10% mice alive at day 84

10% tumour-free mice at day 84

rML 500 ng/kg, ip, qd * 5 * 12

75% mice alive at day 84

65% tumour-free mice at day 84

Control

15 mice alive at day 84

10% tumour-free mice at day 84

Uterusepithelioma T-8 Guérin

Rats

Polysaccharide ("Viscumsäure"), ip, qd * 6

Moderate effect

[133]